GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cytogen Inc (XKRX:217330) » Definitions » Debt-to-Revenue

Cytogen (XKRX:217330) Debt-to-Revenue : 0.67 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cytogen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cytogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩1,245 Mil. Cytogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩13,627 Mil. Cytogen's annualized Revenue for the quarter that ended in Dec. 2024 was ₩22,348 Mil. Cytogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.67.


Cytogen Debt-to-Revenue Historical Data

The historical data trend for Cytogen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytogen Debt-to-Revenue Chart

Cytogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.24 70.79 34.73 5.52 1.36

Cytogen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 4.36 2.86 1.10 0.67

Competitive Comparison of Cytogen's Debt-to-Revenue

For the Diagnostics & Research subindustry, Cytogen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytogen's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cytogen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cytogen's Debt-to-Revenue falls into.


;
;

Cytogen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cytogen's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1244.917 + 13626.645) / 10910.643
=1.36

Cytogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1244.917 + 13626.645) / 22348.236
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Cytogen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cytogen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytogen Business Description

Traded in Other Exchanges
N/A
Address
128, Beobwon-ro, Songpa-gu, A-8 Floor, SK V1 GL Metrocity, Seoul, KOR, 05854
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms.

Cytogen Headlines

No Headlines